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PPiAbstract Objective: To study the effect of gastroesophageal reﬂux disease (GERD) management
by using high dose of proton pump inhibitors (PPIs) on the outcome of uncontrolled asthma.
Study design: The study included 100 patients with their ages ranging from 21 to 69 years. They
presented with uncontrolled asthma (FEV1 less than 80%, with daily rescue medications and more
than one urgent care visit/year). And all patients were on high dose of inhaled oral corticosteroid
(more than 880 lg ﬂuticasone).
F-scale questionnaire was done for the diagnosis of GERD.
Patients with GERD and bronchial asthma received PPIs (40 mg omeprazole) and inhaled oral
corticosteroid (500 lg ﬂuticasone with long acting beta-2 agonist 100 lg salmeterol) for 3 months.
Results: Thirty-one (31%) patients showed combined GERD and bronchial asthma. Twenty-
three patients showed signiﬁcant improvement in asthma control after combined therapy (p value
0.01).
Twenty-three patients showed signiﬁcant improvement in lung function (FEV1 more than 80%),
maintained moderate dose of inhaled corticosteroid without rescue medication (p value 0.01).
Conclusion: GERD is an important cause of uncontrolled asthma and its management
signiﬁcantly improves the uncontrolled asthma and signiﬁcantly reduces the inhaled oral
corticosteroid.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The relationship between gastroesophageal reﬂux disease
(GERD) and asthma has remained controversial since Sir
William Osler ﬁrst described their association in 1892 [16]. A
number of studies (Nagel, Compte) have demonstrated aGERD prevalence ranging from 15 to 82% using pH monitor-
ing in asthma. Distal esophageal stimulation with acid may
cause bronchoconstriction (Mansﬁeld) or may increase bron-
chial reactivity via vagal mechanisms (Herve). In an animal
model, proximal esophageal reﬂux has been shown to cause
microaspiration of gastric acid contents and lead to bron-
choconstriction (Tuchman). Thus, potential mechanisms exist
for GERD to cause asthma symptoms; however, it is unclear
whether or not there is a true causal relationship between
reﬂux episodes and asthma symptoms (Richter). It has beenrculosis.
Table 2 Outcome of F-scale questionnaire in the studied
patients.
GERD No. %
+Ve 31 31%
Ve 69 69%
Total 100 100.0%
Table 3 Relation between combined therapy (inhaled oral
corticosteroid and omeprazole) and pulmonary function (FEV1
more than 80%) before and after combined therapy.
Combined therapy Pulmonary function (FEV1)
Less than
80% (%)
More than
80% (%)
Total
Prior to combined therapy 31 (100%) 0 (0%) 31 (100%)
After combined therapy 8 (25.8%) 23 (74.2%)
X2 12.99
P value 0.01
Chi-Square test was used, P value highly signiﬁcant (P< 0.000).
Table 4 Relation between combined therapy and total asthma
control.
Combined therapy Total asthma control
Uncontrolled
no (%)
Controlled
no (%)
Total
Prior to combined therapy 31 (100%) 0 (0%) 31 (100%)
After combined therapy 8 (25.8%) 23 (74.2%)
X2 9.54
P value 0.01
Chi-Square test was used, P value signiﬁcant (P< 0.05).
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ing factor in the subgroup of patients with ‘‘difﬁcult-to-con-
trol’’ asthma (Chung). In one study (Irwin) of patients with
difﬁcult-to-control asthma, GERD was identiﬁed as the most
common identiﬁable exacerbating factor; however, subjects
were not receiving inhaled steroids but were maintained on
oral steroids, and the diagnosis of GERD was based solely
on clinical grounds in a proportion of study patients. The aims
of this study were to determine the following in a population
with difﬁcult-to-control asthma: (1) the prevalence of GERD
based on symptoms (2) the relationship between the presence
and treatment of GERD and clinical outcome.
Patients and methods
After receiving the approval of our ethics committee at Sohag
Faculty of Medicine and informed consent from the patients
the present study was carried out on 100 patients (78 males
and 22 females) whose age ranged from 21 to 69 years with
mean age of 41.79, during the period from March 2014 to
September 2014. For this study, the inclusion criteria were
symptoms of severe asthma, according to GINA and age over
12 years. The exclusion criteria were abnormal chest X-ray, a
diagnosis of other pulmonary co morbidities or severe extra-
pulmonary disease (see Tables 1–4).
Study design
This was a cohort study. In the ﬁrst visit, patients were evalu-
ated for the inclusion/exclusion criteria and reported a number
of emergency room visits for asthma exacerbations during the
last year. The patients were followed for 6 months, with outpa-
tient clinic visits every 3 months. Lung function test was
performed in the ﬁrst visit and every 3 months thereafter. In
the 6 months of follow-up visit, a doctor re-evaluated the
diagnosis of GERD and, subsequently, re-evaluated the sever-
ity of asthma. The sequence of procedures in the 6 months of
follow-up visit was not ignored.
GERD diagnosis
All of the patients who ﬁrst attended our hospital were asked
to respond to the F-scale questionnaire regardless of their chief
complaints. The questionnaire is a self-report instrument, writ-
ten in simple and easy-to understand language, containing 12Table 1 Demographic data of the studied patients.
Age group Sex Total
Female Male
No. % No. %
20 6 30 8 36% 28 36% 36
30 6 40 6 27% 26 33% 32
40 6 50 4 18% 12 15% 16
50 6 60 2 9% 8 10% 10
60 6 70 2 9% 4 5% 6
Total 22 100% 78 100% 100
In the studied group GERD was diagnosed in 31 cases (31%).questions. As reported previously by [12] and [15], the follow-
ing questions were used to identify.
Symptoms in the F-scale:
(1) Do you get heartburn?
(2) Does your stomach feel bloated?
(3) Does your stomach ever feel heavy after meals?
(4) Do you sometimes subconsciously rub your chest with
your hand?
(5) Do you ever feel sick after meals?
(6) Do you get heartburn after meals?
(7) Do you have an unusual sensation in your throat?
(8) Do you feel full while eating meals?
(9) Do some things get stuck when you swallow?
(10) Do you get bitter liquid coming up into your throat?
(11) Do you get heartburn if you bend over?
(12) Do you burp a lot?
Symptom frequency will be measured on the following
scale: Never = 0; occasionally = 1; sometimes = 2;
Value of proton pump inhibitors therapy 485often = 3; and always = 4. If the patient scores more than 7
points, GERD is considered to be present.
F-scale in Arabic
We will also ask on the presence of risk factors of GERD
as:
– Smoking.
– Coffee and tea.
– Drug history of analgesia as NSAIDS.
– Spicy food.
– Pregnancy in females.
Asthma symptoms
Patients were classiﬁed into controlled or uncontrolled asthma
groups. Patients without persistent asthma symptoms, accord-
ing to GINA criteria and using <1200 lg/day of inhaled
budesonide or equivalent, were classiﬁed into the controlled
asthma group. Patients with persistent symptoms, or with
more than one emergency room visit per year, or with an epi-
sode of near fatal asthma in the follow-up period, and using at
least 1200 lg of budesonide or equivalent, associated with
long-acting beta-2 agonist, were placed in the uncontrolled
asthma group, for the purpose of analysis. Patients that did
not match the criteria for any of these groups were excluded
from this analysis. The group of uncontrolled asthma led to
a subsample of severe asthmatics. Patients who were diagnosed
as having combined GERD and severe bronchial asthma
received combined inhaled oral corticosteroid (500 lg ﬂuticas-
one with long acting beta-2 agonist 100 lg salmeterol) and
high dose of PPIs (40 mg) for three months then pulmonary
function test was done as follow up and clinical evaluation.To estimate the improvement in asthma control, the num-
ber of emergency room visits for asthma exacerbations during
the 1 year of follow-up was compared with the number of
emergency room visits in the year preceding admission, as
reported by the patient during the ﬁrst visit.
Lung function
The lung function test was performed on admission and
3 month follow up visit and was used according to the ATS
recommendation. The forced expiratory volume in the ﬁrst sec-
ond (FEV1) was expressed as a percentage of predicted value
and was used to quantify the degree of airway obstruction.
Statistical analysis
Statistical package for social science (SPSS, version 10) com-
puter software was used for data entry and analysis. T-Test,
Chi-Square test and Fisher’s Exact Test were used for compar-
ison between the results.
Mann–Whitney test was used for correlation between
results.
P value was calculated and considered signiﬁcant if <0.05.
Results
The study included 100 patients. Their ages ranged from 21 to
69 years with mean age of 41.79 years, of them 78 were males
(78%) and 22 were females (22%).
Analysis of patients with uncontrolled bronchial asthma
and GERD receiving combined inhaled corticosteroid and
PPIs showed the following results: There was a highly signiﬁ-
cant relation between combined therapy (inhaled oral steroid
and PPIs) and pulmonary function (FEV1 more than 80%)
after 3 month follow up clinically and functionally.
There was a signiﬁcant relation between the combined ther-
apy and total asthma control (according to GINA guidelines
patients without persistent asthma symptoms, and using
<1200 lg/day of inhaled budesonide or equivalent).
Discussion
Gastroesophageal reﬂux disease occurs frequently among
patients with asthma. This study was carried out to estimate
the prevalence of GERD, as there have been only few preva-
lence assessments for GERD in our geographical location.
Therapy with proton pump inhibitor (PPIs) to improve asthma
control remains controversial, so we sought to evaluate the
efﬁcacy of PPIs in treatment of asthma using objective and
subjective outcome measures.
Overall prevalence of GERD was found to be 31% among
the study subjects. The altered respiratory physiology in
asthma patients may predispose them toward GERD. Such a
higher prevalence of GERD in asthmatics could be attributed
to the following reasons. Respiratory obstruction can result in
negative pleural pressures, thus increasing the pressure gradi-
ent between the thorax and the abdominal cavity and facilitat-
ing the movement of gastric secretions toward the lower
esophageal sphincter (LES), thus promoting reﬂux [6].
Moreover, the diaphragm’s contribution to the sphincter tone
486 K. Alkhayat, A. Mohamedis decreased in asthma. Furthermore, bronchodilator therapies
(both beta-agonists and theophylline) appear to reduce the
LES pressure and increase the pressure gradient across the
LES, thereby promoting the development of GERD [2,10].
The GERD in asthma can be summarized as a reﬂux which
leads to micro aspiration, which occurs in persons with a
heightened bronchial reactivity and an immune system modi-
ﬁcation [5]. Field et al. [4] quoted prevalence ﬁgures for symp-
toms of heartburn and regurgitation of 77% and 55% of
asthmatics, respectively. Harding et al. [7] retrospectively
examined 199 asthmatics, of whom one third were classiﬁed
as severe, and found 164 subjects (82%) with symptoms of
GERD. Using a systematic protocol, Irwin et al. [9] examined
42 patients with difﬁcult asthma and found that GERD was
the most common factor making asthma difﬁcult to treat.
However, their deﬁnition of GERD included the presence of
prominent symptoms and all patients recruited into their study
had to have received at least 10 mg of oral prednisolone every
other day for at least 3 consecutive months per year and were
not receiving inhaled steroids which reﬂected asthma treatment
at that time. Systemic steroids have been shown to increase
both proximal and distal GERD in asthma patients and may
have potentiated reﬂux disease [13]. This may have contributed
to their high prevalence of reﬂux. These factors make this
study difﬁcult to compare directly with our ﬁndings. In agree-
ment with our study Walter et al. [18] reported that empirical
use of PPI therapy for adults with asthma resulted in sta-
tistically signiﬁcant improvement in the morning PEF rate.
Leggett et al. [14] studied 42 patients with difﬁcult to con-
trol asthma, and found that GERD was the most common fac-
tor that contributed to making asthma difﬁcult to control.
GERD was a deﬁnite factor in 64% of asthmatics who had
a favorable response to medical antireﬂux therapy.
DeMeester et al. [3] evaluated 77 asthmatics with suspected
reﬂux-related respiratory symptoms (persistent cough, wheez-
ing, and/or recurrent pneumonia) and found that respiratory
symptoms occurred during or within 3 min after a reﬂux epi-
sode in 22% patients.
In a large study, and the only one to use Ph monitoring,
Harding et al. [6] evaluated 30 nonsmoking adult asthmatics
with gastroesophageal reﬂux before and after 3 months of
omeprazole therapy. Gastroesophageal reﬂux was deﬁned by
symptoms and abnormal 24-h esophageal pH testing. During
the 4-week pretherapy phase, patients recorded reﬂux and
asthma symptom scores and PEF upon awakening, 1 h after
dinner, and at bedtime. Patients began 20 mg/d omeprazole,
and the dose was titrated until acid suppression was docu-
mented by 24-h pH test. Patients remained on this acid sup-
pressive dose for 3 months. Treatment with omeprazole
resulted in improvements in asthma symptoms in 67% of
patients, and pulmonary function in 20% of patients.
Champion et al. [1] demonstrated that omeprazole 40 mg
not only reduces acid secretion but also reduces bile reﬂux
by 90%. On the contrary, Julian et al. [11] found that PPI does
not relate to asthma outcome, this may be due to non acid
reﬂux as acid suppression does not protect against reﬂux and
aspiration of other components of gastric contents.
Although the majority of GERD can be managed success-
fully with medical therapy, patients with severe complications,
refractory disease, or with a severely incompetent lower eso-
phageal sphincter should be referred for surgical evaluation
[8]. Antireﬂux surgery attempts to restore sphinctercompetence by wrapping the gastric fundus around the
esophagus, called fundoplication. When performed skillfully,
this procedure will restore LES, reduce reﬂux, and heal peptic
esophagitis. The potential advantage of surgery over medical
therapy is that the reduction in esophageal acid exposure is
greater, and Rubaish [17] found that overall, 34% of patients
were free of asthma symptoms postoperatively, 42% were
improved, and 24% were unchanged.
Conclusion
GERD was associated with uncontrolled asthma in 31% of
cases. Combined treatment of GERD and bronchial asthma
signiﬁcantly improves the uncontrolled asthma and signiﬁ-
cantly reduces the dose of inhaled oral corticosteroid. So,
screening for GERD may be done in patients with refractory
asthma.Conﬂict of interest
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